NEX Health Intelligence secures €1M to tackle hospital infection spread

Healthtech
startup NEX Health Intelligence has raised €1 million in a pre-seed funding
round led by Brighteye Ventures, with participation from Adeline Arts &
Science, AFI Ventures, Momentous Ventures, the Conception X Angel Syndicate and
a group of industry angel investors.

Healthcare-associated
infections affect a significant proportion of hospital patients and contribute
to longer hospital stays, operational disruption and rising healthcare costs.
Highly resistant infections, in particular, continue to pose growing clinical
and operational challenges for healthcare systems globally.

NEX
Health Intelligence develops an AI-powered infection intelligence platform
designed to help hospitals detect, predict and prevent healthcare-associated
infections before they spread. The platform aims to enable hospitals to
identify transmission risks earlier and implement more targeted infection
prevention measures.

The
company was founded by Dr Ashleigh Myall after his experience working on the
NHS COVID-19 response highlighted how quickly infections can spread between
vulnerable patients within hospitals. He later partnered with Dr Chang Ho Yoon
to explore how AI could be applied to infection prevention and hospital safety.

While
supporting the NHS COVID-19 response, I realised the real challenge wasn’t just
the number of admissions – it was how quickly infections spread between
vulnerable patients already inside hospitals,

said Dr
Ashleigh Myall, who explained that the idea for NEX emerged during his PhD at
Imperial, where he began developing AI systems to predict how infections could
spread within hospitals.

Following
its latest product release, the company reported a significant increase in
infection control compliance rates. To date, NEX says its platform has
supported infection safety across more than 40,000 patient admissions
internationally.

NEX is
currently working with NHS organisations in the United Kingdom, including
evaluation projects across two London NHS Trusts and a deployment in the North
West of England. Internationally, the company is operating at a military
hospital in Southeast Asia and is expanding through projects in Malaysia.

The new
funding will support the company’s expansion across UK and international
hospitals, alongside regulatory and clinical safety work and the generation of
clinical and economic evidence from live deployments.